Polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study Meeting Abstract


Authors: Sehn, L. H.; Herrera, A. F.; Matasar, M. J.; Kamdar, M.; Assouline, S.; Hertzberg, M.; Kim, T. M.; Kim, W. S.; McMillan, A.; Ozcan, M.; Hirata, J. M.; Penuel, E.; Cheng, J.; Ku, G.; Flowers, C. R.
Abstract Title: Polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study
Meeting Title: 60th Annual Meeting of the American Society of Hematology (ASH)
Journal Title: Blood
Volume: 132
Issue: Suppl. 1
Meeting Dates: 2018 Dec 1-4
Meeting Location: San Diego, CA
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2018-11-29
Language: English
ACCESSION: WOS:000454837605059
PROVIDER: wos
Notes: Meeting Abstract: 1683 -- Source: Wos